CTS SCIENTIFIC PROGRAM 2017 – Preliminary Program
Monday, October 30, 2017, 11:00 – 17:30

Held in conjunction with the CHEST Annual Meeting
Room 716B, 700 Level - Metro Toronto Convention Centre, Toronto, Ontario

Program Chair: Dr. John Gjevre

11:00 – 11:20 Advances in Pulmonary Rehabilitation for ILD
Dr. Julie Morisset, Université de Montréal, Montréal, Québec

This session will present the current state of the art scientific knowledge on pulmonary rehabilitation in patients with interstitial lung disease. In this session, participants will:

1. Review the latest literature in pulmonary rehabilitation in ILD.
2. Understand the benefits of pulmonary rehabilitation for patients with ILD.

11:20 – 11:40 The Impact of Comorbidities on Tuberculosis Epidemiology in Migrants to Canada
Dr. James Johnston, University of British Columbia, Vancouver, BC

To accelerate declines in Tuberculosis (TB) incidence in low incidence countries, new strategies are needed. Latent TB screening and treatment in high-risk migrants may be a viable strategy to reduce TB incidence, but robust data to inform screening policies is lacking. In this presentation I will discuss the impact of comorbid conditions on TB incidence in a cohort of over one million migrants to British Columbia, Canada. In this session, participants will:

1. Review the drivers of TB risk in migrants to low incidence regions.
2. Understand the interaction between demographic and comorbid factors to produce TB risk.

11:40 – 12:00 Non-Invasive Ventilation in Children; Update from the 2017 CTS Pediatric Home-Based Ventilation Clinical Practice Guideline
Dr. David Zielinski, McGill University, Montréal, Québec

Home based non-invasive ventilation in children has been rapidly increasing over the last 10 years. We will review key recommendations from the 2017 Canadian Thoracic Society Pediatric Home Mechanical Ventilation Clinical Practice Guideline, focusing on key recommendations around provision of Non-Invasive Ventilation (NIV) at home in children. The importance of identifying children, testing them and ensuring the proper program infrastructure is in place for long term care will be discussed. At the end of this session, participants will be able to:

1) Identify children at risk for long term home mechanical ventilation
2) Recognize when to screen for Sleep Disordered Breathing in Children at risk
3) Summarize special consideration for non-invasive ventilation at home in children.

12:00 – 13:30 Break
13:30 – 14:30 Debate: Combination Therapy as the standard of care for pulmonary arterial hypertension?
Pro: Dr. Andrew Hirsch, Montréal, Québec
Con: Dr. George Chandy, Ottawa, Ontario

The data regarding up-front combination therapy will be reviewed and advantages and disadvantages of this approach versus other treatment algorithms will be debated. At the end of this session, participants will be able to:

1. Understand the difference between up-front combination therapy versus a step-up treatment approach in pulmonary arterial hypertension
2. Have reviewed the latest data regarding the potential advantages of up-front combination therapy on important clinical outcomes in PAH
3. Understand alternative treatment approaches such as mono-therapy and step-up combination therapy in the treatment of PAH.

14:30 – 15:15 Break

15:15 – 15:45 Comprehensive Management of Fibrotic ILD
Deborah Assayag, McGill University, Montréal, Québec

This session will summarize the existing evidence and CTS expert recommendations for management of fibrotic interstitial lung diseases. Topics presented will include pulmonary rehabilitation, pharmacotherapy, advanced care planning, and lung transplantation. At the end of this session, participants will be able to:

1. Understand the role of pulmonary rehabilitation in the care of patients with fibrotic ILD.
2. Identify patients with fibrotic ILD who should be referred for lung transplant.
3. Become familiar with medications to manage debilitating symptoms of fibrotic ILD.

15:45 – 16:15 CTS COPD Guideline Update 2017
Dr. Jean Bourbeau, McGill University, Montréal, Québec

Since the last published Canadian Thoracic Society (CTS) COPD guideline in 2007 and the 2008 update – highlights for primary care, many new clinical trials have challenged COPD treatment practices. Identifying important new evidence and assessing whether these findings warrant change in current practice is needed. Furthermore, a new Canadian statement and position on the pharmacotherapy of COPD is timely considering the recent Global Initiative for Chronic Obstructive Lung Disease (GOLD) Report 2017. In the GOLD Report 2017 alike the CTS COPD guideline, severity of airflow limitation is no longer considered in the treatment algorithm. Pharmacotherapy is modified according to symptom burden and risk of COPD exacerbations, which determine the ABCD categorization of patients for therapeutic decisions. The current Canadian position paper provides the reader with an update on pharmacotherapy of patients with COPD as reviewed by the CTS. After this session, participants will be able to:

1. Summarize the literature on topics relevant to the pharmacological therapy of patients with stable COPD; and
2. Provide evidence-based and expert-informed key messages for the pharmacological therapy of stable COPD.

16:15 – 16:30 Break
Chronic obstructive pulmonary disease (COPD) is the 3rd leading cause of mortality worldwide. None of the available therapies as currently applied modify disease progression or reduce mortality. With the advent of -omics technology and better phenotyping of patients, precision health is enabled in COPD. This talk will focus on how clinicians can use omics technology now and in the future to guide therapeutic choices and optimize health outcomes of patients with COPD.